Skip to main content

Anti-Ulcer Agents

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Jeil Pharmaceutical
Jeil PharmaceuticalKorea - Seoul
1 program
1
Cohort 1Phase 11 trial
Active Trials
NCT03383042Completed115Est. Apr 2019
Onconic Therapeutics
1 program
1
coadministration of JP-1366 and aceclofenacPhase 11 trial
Active Trials
NCT05181124Completed88Est. Mar 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Onconic Therapeuticscoadministration of JP-1366 and aceclofenac
Jeil PharmaceuticalCohort 1

Clinical Trials (2)

Total enrollment: 203 patients across 2 trials

NCT05181124Onconic Therapeuticscoadministration of JP-1366 and aceclofenac

Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

Start: Mar 2021Est. completion: Mar 202188 patients
Phase 1Completed

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Start: Dec 2017Est. completion: Apr 2019115 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.